It is to buy the FDA approved treatment via the acquisition of private pharma group ToConceive LLC.
The average cost of IVF Treatment in the US is $13,000, while three months of this treatment is $120.
Chief executive of M Pharma Brian Keane told investors: “This acquisition is our entry into the women’s health market to complement our existing obesity portfolio.
“We are confident this product presents a potential breakthrough in the women’s health space due to its ease of use as a personal lubricant and its effectiveness, both clinically and from a cost standpoint.”
The purchase is subject to further due diligence and stock exchange approval, and would see M Pharma issue 20 million shares and agree to pay a 5% royalty on sales.
The product is applied on the outside of a woman’s genitalia and stimulates a natural self-produced lubrication and balances the pH to help the sperm to survive.
It also gives the sperm the ability, or capacity, to fertilise the ovum for conception - an important process called sperm capacitation.
In addition to its recent acquisition of C-103, a reformulation of orlistat from Chelatexx, M Pharma will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights.
Story by ProactiveInvestors